Regencell Bioscience's 15min chart triggers MACD Death Cross, KDJ Death Cross.

According to the 15-minute chart for Regencell Bioscience, the MACD Death Cross and KDJ Death Cross signals were triggered on October 9th at 11:15. This suggests that the stock price has the potential to continue declining, and the momentum is shifting towards the downside, which may result in a further decrease in value.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has been the subject of intense market scrutiny following recent technical indicators signaling a potential downturn. According to the 15-minute chart, the MACD (Moving Average Convergence Divergence) and KDJ (Kaufman Adaptive Moving Average) Death Crosses were triggered on October 9th at 11:15, suggesting a shift in momentum towards the downside.

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a potential change in trend. Similarly, the KDJ Death Cross is a bearish signal that appears when the KDJ line crosses below the 50-day moving average. Both indicators are widely used by traders to gauge market sentiment and predict price movements.

Regencell, a biopharmaceutical company specializing in Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders, has experienced significant volatility in its stock price. In 2025 alone, the stock price surged from mere pennies to a 52-week high of $83.60 before collapsing by around 74% from the peak. Despite this volatility, the stock has shown resilience, with recent price movements driven by positive trial results and index inclusions.

However, the technical indicators suggest that the current momentum may be shifting. The MACD and KDJ Death Crosses indicate that the stock price could continue to decline, potentially leading to further decreases in value. This is particularly concerning given the company's high-risk, high-reward nature and its lack of commercialized products or revenue.

Investors should be cautious when interpreting these signals, as technical indicators are not infallible. They should also consider the company's fundamentals and the broader market conditions. Regencell's success will ultimately depend on its ability to execute on its clinical and commercial goals.